false
0001434868
0001434868
2025-10-07
2025-10-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
October 7, 2025
Esperion
Therapeutics, Inc.
(Exact name of registrant as specified in its
charter)
| Delaware |
|
001-35986 |
|
26-1870780 |
(State
or other jurisdiction of
incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
3891
Ranchero Drive, Suite 150
Ann
Arbor, MI |
| (Address
of principal executive offices) |
48108
(Zip Code)
Registrant’s telephone number,
including area code: (734) 887-3903
Not Applicable
Former name or former address, if changed since
last report
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant
to Section 12(b) of the Act:
| Title of each class |
|
Trading
Symbol |
|
Name of each exchange
on which registered |
| Common Stock, par value $0.001 per share |
|
ESPR |
|
NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging
growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 8.01. Other Events.
On October 7, 2025, Esperion Therapeutics, Inc.
(the “Company”) posted an updated corporate presentation to its website at https://www.esperion.com/investors-media. A copy
of the updated corporate presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated
herein by reference. Reference to the Company’s website is for inactive textual reference only and the content of the website should
not be deemed incorporated by reference into this Current Report on Form 8-K
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. |
|
Description |
| 99.1 |
|
Corporate
Presentation dated October 2025. |
| 104 |
|
The cover
page from this Current Report on Form 8-K, formatted in Inline XBRL. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| Date: October 7, 2025 |
Esperion Therapeutics, Inc. |
| |
|
| |
By: |
/s/
Sheldon L. Koenig |
| |
|
Sheldon
L. Koenig |
| |
|
President
and Chief Executive Officer |
